Does Interval between Hysterectomy and Start of Radiation Treatment Influence Survival in Early Stage Endometrial Carcinoma? A National Cancer Database Analysis

COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation

PURPOSE

The purpose of this study was to highlight the importance of timely brachytherapy treatment for patients with gynecologic, breast, and prostate malignancies, and provide a framework for brachytherapy clinical practice and management in response to the COVID-19 pandemic.

METHODS AND MATERIALS

We review amassing evidence to help guide the management and timing of brachytherapy for gynecologic, breast, and prostate cancers. Where concrete data could not be found, peer-reviewed expert opinion is provided.

RESULTS

There may be a significant negative impact on oncologic outcomes for patients with gynecologic malignancies who have a delay in the timely completion of therapy. Delay of prostate or breast cancer treatment may also impact oncologic outcomes. If a treatment delay is expected, endocrine therapy may be an appropriate temporizing measure before delivery of radiation therapy. The use of shorter brachytherapy fractionation schedules will help minimize patient exposure and conserve resources.

CONCLUSIONS

Brachytherapy remains a critical treatment for patients and may shorten treatment time and exposure for some. Reduced patient exposure and resource utilization is important during COVID-19. Every effort should be made to ensure timely brachytherapy delivery for patients with gynecologic malignancies, and endocrine therapy may help temporize treatment delays for breast and prostate cancer patients. Physicians should continue to follow developing institutional, state, and federal guidelines/recommendations as challenges in delivering care during COVID-19 will continue to evolve.

The impact of waiting intervals on survival outcomes of patients with endometrial cancer: A systematic review of the literature

The purpose of the present systematic review is to summarize the available evidence concerning the impact of investigated intervals of treatment (diagnosis to surgery and surgical treatment to adjuvant therapy) on survival outcomes of endometrial cancer patients. We searched Medline, Scopus, Clinicaltrials.gov, EMBASE, and Google Scholar databases from inception until July 31st 2019. All observational studies were considered eligible for inclusion. Investigated outcomes were retrieved and analyzed as well as factors that influenced the extent of wait intervals. Overall, 12 articles were included that investigated the influence of wait intervals on survival outcomes of 773,185 patients. We observed that the proposed cut-off values for interval periods, the reported survival outcomes as well as the tumor characteristics of included patients varied significantly among the studies that were included. Given these differences, meta-analysis of survival outcomes was not possible. The most common cut-off for the time to surgery interval was 6 weeks and for the time to adjuvant treatment 9 weeks. The percentage of patients that was treated within this limit ranged between 24 and 74 %. Given this information we believe that the optimal interval between diagnosis and surgical treatment of endometrial cancer patients should not exceed eight weeks (keeping in mind that surgery within the first two weeks may be a negative prognostic factor), whereas between surgery and adjuvant therapy should be limited to a maximum of nine weeks. Future studies should evaluate factors that seem to influence the extent of waiting intervals to help determine the limitations of healthcare systems.

A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer

OBJECTIVE

Advances in minimally invasive surgery, particularly with robotic surgery, have resulted in improved peri-operative outcomes in patients with endometrial cancer. In addition, randomized trials have shown that addition of adjuvant radiotherapy following surgery improves loco-regional disease control among stage I intermediate-risk endometrial cancer patients. We aimed to investigate the efficacy and safety of combined treatment of robotic surgery and adjuvant radiotherapy in this patient population.

METHODS

A single-center retrospective study was conducted on stage I endometrioid-type endometrial cancer patients with intermediate-risk features (<50% myometrial involvement and grade 2-3 histopathology, or >50% myometrial involvement and grade 1-2 histopathology) treated with hysterectomy and adjuvant radiotherapy between January 2010 and December 2015. Data on surgery and radiotherapy were collected and correlated with clinical and surgical outcomes using log-rank. Oncologic outcomes were then compared between robotic surgery and laparotomy.

RESULTS

A total of 179 intermediate-risk endometrial cancer patients were identified, of whom 135 (75.4%) received adjuvant radiotherapy and were included in the final analysis. Median age at diagnosis was 63 years (range 40-89) and median follow-up was 4.7 years (range 1.1-8.8). Seventy-seven patients (57%) underwent robotic surgery and 58 patients (43%) underwent laparotomy. Surgical staging with lymph node dissection was performed on 79.3% of the patients. The majority of patients (79.3%) received vaginal brachytherapy as part of adjuvant radiotherapy, while 20.7% received external-beam radiotherapy. Among the entire cohort, eight (5.9%) patients recurred and all eight recurrences occurred in the robotic surgery group; no recurrence was found in the laparotomy group. This translated into 5 year disease-free survival of 100% in the laparotomy group, compared with 91.8% in the robotic surgery group (p=0.005). No difference in overall survival was found between the two groups (p=0.51).

CONCLUSION

Oncologic outcomes for stage I intermediate-risk endometrial cancer treated with hysterectomy and adjuvant radiotherapy at our institution are comparable to the previously published literature. The higher recurrence rate observed with robotic surgery at our institution has not been observed previously and requires further investigation.